Cremer Jochen, Heinemann Markus K, Mohr Friedrich Wilhelm, Diegeler Anno, Beyersdorf Friedhelm, Niehaus Heidi, Ensminger Stephan, Schlensak Christian, Reichenspurner Hermann, Rastan Ardawan, Trummer Georg, Walther Thomas, Lange Rüdiger, Falk Volkmar, Beckmann Andreas, Welz Armin
Klinik für Herz- und Gefäßchirurgie, UK Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Klinik und Poliklinik für Herz, Thorax- und Gefäßchirurgie, Universitätsmedizin Mainz, Mainz, Germany.
Thorac Cardiovasc Surg. 2014 Dec;62(8):639-44. doi: 10.1055/s-0034-1395972. Epub 2014 Nov 21.
Surgical aortic valve replacement is still considered the first-line treatment for patients suffering from severe aortic valve stenosis. In recent years, transcatheter aortic valve implantation (TAVI) has emerged as an alternative for selected high-risk patients. According to the latest results of the German external quality assurance program, mandatory by law, the initially very high mortality and procedural morbidity have now decreased to approximately 6 and 12%, respectively. Especially in Germany, the number of patients treated by TAVI has increased exponentially. In 2013, a total of 10.602 TAVI procedures were performed. TAVI is claimed to be minimally invasive. This is true concerning the access, but it does not describe the genuine complexity of the procedure, defined by the close neighborhood of the aortic valve to delicate intracardiac structures. Hence, significant numbers of life-threatening complications may occur and have been reported. Owing to the complexity of TAVI, there is a unanimous concordance between cardiologists and cardiac surgeons in the Western world demanding a close heart team approach for patient selection, intervention, handling of complications, and pre- as well as postprocedural care, respectively. The prerequisite is that TAVI should not be performed in centers with no cardiac surgery on site. This is emphasized in all international joint guidelines and expert consensus statements. Today, a small number of patients undergo TAVI procedures in German hospitals without a department of cardiac surgery on site. To be noted, most of these hospitals perform less than 20 cases per year. Recently, the German Cardiac Society (DGK) published a position paper supporting this practice pattern. Contrary to this statement and concerned about the safety of patients treated this way, the German Society for Thoracic and Cardiovascular Surgery (DGTHG) still fully endorses the European (ESC/EACTS) and other actual international guidelines and consensus statements. Only the concomitance of departments for cardiac surgery and cardiology on site can provide optimal TAVI care. This commentary by the DGTHG delineates the data and resources upon which its opinion is based.
外科主动脉瓣置换术仍然被认为是重度主动脉瓣狭窄患者的一线治疗方法。近年来,经导管主动脉瓣植入术(TAVI)已成为部分高危患者的替代治疗方案。根据德国法定的外部质量保证项目的最新结果,最初极高的死亡率和手术并发症发生率现已分别降至约6%和12%。特别是在德国,接受TAVI治疗的患者数量呈指数级增长。2013年,总共进行了10602例TAVI手术。TAVI被宣称具有微创性。就手术入路而言确实如此,但这并未描述该手术真正的复杂性,主动脉瓣紧邻心脏内精细结构决定了其复杂性。因此,可能会出现并已报告了大量危及生命的并发症。由于TAVI的复杂性,西方世界的心脏病专家和心脏外科医生一致认为,在患者选择、干预、并发症处理以及术前和术后护理方面,都需要心脏团队紧密合作。前提是TAVI不应在没有现场心脏外科手术的中心进行。所有国际联合指南和专家共识声明都强调了这一点。如今,德国一些没有心脏外科科室的医院也有少数患者接受TAVI手术。需要注意的是,这些医院大多数每年的手术量不到20例。最近,德国心脏病学会(DGK)发表了一篇立场文件支持这种做法。与该声明相反,出于对以这种方式治疗的患者安全性的担忧,德国胸心血管外科学会(DGTHG)仍然完全支持欧洲(ESC/EACTS)及其他现行国际指南和共识声明。只有现场同时具备心脏外科和心脏病学科室,才能提供最佳的TAVI治疗。DGTHG的这篇评论阐述了其观点所依据的数据和资源。